Jump to: What is Mounjaro? | How do you get a prescription for Mounjaro? | Does Mounjaro have side effects?
The cost of Mounjaro depends on where you get it and how much support you want to develop healthy habits alongside the medication.
Mounjaro will be the cheapest when purchased from pharmacies in the UK, like Boots, Superdrug, or Asda Online Doctor, because they don’t include support from a registered nutritionist or dietitian.
Online pharmacies will provide the medication without additional support to help develop healthy habits.
Mounjaro costs for online pharmacies in the UK as of September 2024:
- Boots: £219 for the first four-week supply of 2.5 mg, rising to £249 for the highest dose of 15 mg
- Superdrug: £215 for the first four-week supply of 2.5 mg, rising to £245 for the highest dose of 15 mg
- Asda Online Doctor: £179 for the first four-week supply of 2.5 mg, rising to £204
Second Nature’s Mounjaro programme is more expensive than the high-street pharmacies’ because it includes the support of a registered dietitian or nutritionist.
The cost of Mounjaro starts from £229 a month with Second Nature’s Mounjaro weight-loss programme and rises to £299 at the higher doses.
Our programme is delivered entirely via an app and is designed by dietitians and psychologists to help you develop healthy habits, calm down the feeling of food noise, and keep weight loss off in the long term.
While our Wegovy and Mounjaro weight-loss programmes are private and not currently used by the NHS, we’ve built the programmes focusing on scientific evidence, patient safety, and data security.
We hope that our 6+ years of working with the NHS and building a track record of effective weight-loss results will give you peace of mind to give us a try.
What is Mounjaro?
Mounjaro is a dual-function medication for individuals living with type 2 diabetes and obesity. Its active ingredient is tirzepatide.
Tirzepatide is sold under the brand name Mounjaro in the UK, or Zepbound for obesity in the U.S., and manufactured by the pharmaceutical company Eli Lilly.
Tirzepatide mimics two hormones in the body: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP).
When we eat food, our gut releases a hormone that helps the body regulate hunger and blood sugar levels. This hormone is called GLP-1 (glucagon-like peptide-1).
The actions of GLP-1 are the target of Mounjaro and other medications like Wegovy, Saxenda, and Ozempic.
This class of medications are known as GLP-1 receptor activators (GLP-1s). They mimic the actions of the hormone GLP-1 to activate the GLP-1 receptors.
GLP-1s improve insulin function to lower blood sugar levels and delay gastric emptying, decreasing appetite. GLP-1s also communicate with the brain’s appetite control centre, the hypothalamus, to reduce food-seeking behaviour.
Separately to GLP-1s, the other hormone that Mounjaro mimics is called GIP.
GIP is a hormone released in response to food that helps regulate blood sugar levels and helps our fat cells ‘absorb’ more excess energy, preventing fat from being stored in the liver or pancreas.
GIP also has receptors in the brain, similar to GLP-1, and scientists believe it’s also involved in regulating appetite.
The medications that mimic GIP are known as GIP mimetics. These additional actions are the target of Mounjaro.
So, tirzepatide has a dual function that mimics two hormones in the body that support blood glucose levels and weight loss.
How do you get a prescription for Mounjaro?
For Second Nature’s Mounjaro programme, you’ll qualify for Mounjaro if you have a BMI of over 27 and also meet other eligibility criteria.
However, we’re unable to share this information online, and you must complete our health quiz first for us to check your eligibility.
If you’re living with type-2 diabetes, to receive a Mounjaro (tirzepatide) prescription via the NHS in the UK, here are the eligibility criteria confirmed by NICE:
- Triple therapy with metformin and two other oral antidiabetic drugs is ineffective, not tolerated or contraindicated, and
- they have a body mass index (BMI) of 35 kg/m2 or more and specific psychological or other medical problems associated with obesity,
- or they have a BMI of less than 35 kg/m2, and:
- insulin therapy would have significant occupational implications, or
- weight loss would benefit other significant obesity-related complications.
Lower BMI thresholds (usually reduced by 2.5 kg/m2) apply for people from South Asian, Chinese, other Asian, Middle Eastern, Black African or African-Caribbean family backgrounds.
Does Mounjaro have side effects?
All medications have potential side effects, and Mounjaro is no different. The most common side effects of Mounjaro are nausea, constipation, vomiting, and other symptoms affecting the gastrointestinal (GI) tract, like diarrhoea.
You might also experience less common side effects like tiredness or headaches.
These symptoms most commonly occur around the time of the injection, during dose escalation, and are typically transient and will ease after you’ve adapted to the medication.
However, everyone responds differently to these medications; some people won’t experience any side effects, while others will have to discontinue their medication due to the discomfort the side effects cause.
Not a magic pill
Weight-loss injections are most effective when combined with a healthier lifestyle. They can help kickstart weight loss while you commit to developing healthier habits.
Mounjaro and other weight loss injections, like Ozempic and Wegovy, can allow you to make lifestyle changes to support long-term weight loss.
These medications can help silence food-related thoughts and give you a boost of confidence with more immediate weight-loss results.
They can also buy you the time and headspace to understand why your body may have struggled to lose weight and build new long-term healthy habits.
The core focus of our medication programmes is to calm down the feeling of food noise, lower your cravings, and allow you to build healthier habits to keep the weight off for good.
The ultimate goal is to make losing weight feel second nature.
